Investors in Aardvark Therapeutics Have Until October 13 to Seek Lead Plaintiff Role

New York, New York, September 6, 2026, Faruqi & Faruqi, LLP, a leading national securities law firm, is reminding investors who purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) securities of the impending deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The deadline to file the motion is October 13, 2026.

The lawsuit, filed against Aardvark Therapeutics and its executives, alleges that the company and its management violated federal securities laws by making false and misleading statements about the safety and future prospects of its lead drug, ARD-101. Specifically, the complaint claims that the company's initial public offering (IPO) documents and subsequent public statements were negligently prepared, containing untrue statements of material fact or omitting necessary information to make the statements misleading.

According to the press release, the offering documents, which were filed on February 13, 2025, and incorporated into the Registration Statement, stated that ARD-101 was a safe and promising drug. However, the truth began to emerge on February 27, 2026, when Aardvark announced the voluntary pause of its Phase 3 HERO trial due to "reversible cardiac observations" at higher therapeutic doses. This announcement caused Aardvark's stock price to plummet by 56.2% to close at $5.47 per share on March 2, 2026.

On May 14, 2026, the U.S. Food and Drug Administration (FDA) placed a full clinical hold on Aardvark's investigational new drug application (IND) for ARD-101, impacting all ongoing clinical studies, including the Phase 3 HERO trial and the Phase 3 open-label extension (OLE) trial. This news further depressed Aardvark's stock price by 32.1%, closing at $4.57 per share.

Faruqi & Faruqi, LLP, which has recovered hundreds of millions of dollars for investors since its founding in 1995, is encouraging investors who purchased Aardvark's common stock between February 13, 2025, and May 14, 2026, to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Extension 1310) to discuss their legal rights and potential claims. The firm has also called for anyone with information about Aardvark's conduct to come forward.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of the class members and will direct and oversee the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to remain an absent class member without affecting their ability to share in any recovery.

To learn more about the lawsuit, investors can visit Faruqi & Faruqi's website at www.faruqilaw.com/AARD or contact the firm directly. Faruqi & Faruqi, LLP, with offices in New York, Pennsylvania, California, and Georgia, is committed to representing investors in securities litigation and has a proven track record of success.